GB886553A - Substitutes for blood plasma and process for their manufacture - Google Patents

Substitutes for blood plasma and process for their manufacture

Info

Publication number
GB886553A
GB886553A GB2491/59A GB249159A GB886553A GB 886553 A GB886553 A GB 886553A GB 2491/59 A GB2491/59 A GB 2491/59A GB 249159 A GB249159 A GB 249159A GB 886553 A GB886553 A GB 886553A
Authority
GB
United Kingdom
Prior art keywords
hydrolysate
cross
solution
yield
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB2491/59A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Farbwerke Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG, Farbwerke Hoechst AG filed Critical Hoechst AG
Publication of GB886553A publication Critical patent/GB886553A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A substitute for blood plasma is produced by (i) subjecting a collagen degradation product to mild hydrolytic degradation to yield a hydrolysate of molecular weight of 2,000 to 20,000, e.g. 5,000 to 10,000, cross-linking the hydrolysate at pH about 7 by reaction with a proportion of a polyfunctional isocyanate smaller than that calculated for the total reaction of all the amino and guanidino groups present in the hydrolysate; (ii) cross-linking a collagen degradation product at pH about 7 by reaction with a proportion of a polyfunctional isocyanate smaller than that calculated for the total reaction of all the amino and guanidino groups present, subjecting the cross-linked product to mild hydrolytic degradation to yield a hydrolysate having a molecular weight of 10,000 to 100,000, e.g. 30,000 to 60,000; and the solution obtained from (i) or (ii) is adjusted to pH about 7, if it does not have that value, and is rendered isotonic. The collagen degradation product may be gelatin. The proportion of the isocyanate may amount to 20% to 80% of that calculated for the total reaction of all the amino and guanidino groups present. The isocyanate may be aromatic, hydroaromatic or aliphatic of formula OCN-(CH2)x-NCO where X is a whole number from 2 to 20, e.g. hexamethylene, diisocyanate, which may be used in solution or suspension in tetrahydrofurane, acetone or water. The concentration of the cross-linked hydrolytic degradation product in solution may be 4% to 6% and the solution may be rendered isotonic by addition of sodium chloride or physiological salt mixture. The hydrolysis may be acidic, alkaline, or fermentative, e.g. using trypsin, pepsin and tissue enzymes. An aqueous gelatin solution of 5% strength may be (i) hydrolysed under pressure at 120 DEG C. to yield a hydrolysate having a molecular weight of 5,000 to 10,000 and the hydrolysate cross-linked with hexamethylene diisocyanate at 20 DEG C. to 30 DEG C., or (ii) may be cross-linked by reaction with hexamethylene diisocyanate at 20 DEG C. to 30 DEG C. and subsequently hydrolysed under pressure at 120 DEG C. to yield a hydrolysate having a molecular weight of 10,000 to 100,000.ALSO:A substitute for blood plasma is produced by (i) subjecting a collagen degradation product to mild hydrolytic degradation to yield a hydrolysate of molecular weight of 2000 to 20,000, e.g. 5000 to 10,000, cross-linking the hydrolysate at pH about 7 by reaction with a proportion of a polyfunctional isocyanate smaller than that calculated for the total reaction of all the amino and guanidino groups present in the hydrolysate; or (ii) cross-linking a collagen degradation product at pH about 7 by reaction with a proportion of a polyfunctional isocyanate smaller than that calculated for the total reaction of all the amino or guanidino groups present, subjecting the cross-linked product to mild hydrolytic degradation to yield a hydrolysate having a molecular weight of 10,000 to 100,000, e.g. 30,000 to 60,000; and the solution obtained from (i) or (ii) is adjusted to pH about 7, if it does not have that value, and is rendered isotonic. The collagen degradation product may be gelatin. The proportion of the isocyanate may amount to 20 to 80% of that calculated for the total reaction of all the amino and guanidino groups present. The isocyanate may be aromatic, hydro-aromatic, or aliphatic of formula OCN-(CH2)x-NCO where x is a whole number from 2 to 20, e.g. hexamethylene diisocyanate, which may be used in solution or suspension in tetrahydrofurane, acetone or water. The concentration of the cross-linked hydrolytic degradation product in solution may be 4 to 6% and the solution may be rendered isotonic by addition of sodium chloride or physiological salt mixture. The hydrolysis may be acidic, alkaline, or fermentative, e.g. using trypsin, pepsin and tissue enzymes. An aqueous gelatine solution of 5% strength may be (i) hydrolysed under pressure at 120 DEG C. to yield a hydrolysate having a molecular weight of 5000 to 10,000 and the hydrolysate cross-linked with hexamethylene diisocyanate at 20 DEG to 30 DEG C., or (ii) may be cross-linked by reaction with hexamethylene diisocyanate at 20 DEG to 30 DEG C. and subsequently hydrolysed under pressure at 120 DEG C. to yield a hydrolysate having a molecular weight of 10,000 to 100,000.
GB2491/59A 1958-01-22 1959-01-22 Substitutes for blood plasma and process for their manufacture Expired GB886553A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE886553X 1958-01-22

Publications (1)

Publication Number Publication Date
GB886553A true GB886553A (en) 1962-01-10

Family

ID=6833378

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2491/59A Expired GB886553A (en) 1958-01-22 1959-01-22 Substitutes for blood plasma and process for their manufacture

Country Status (1)

Country Link
GB (1) GB886553A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3239420A (en) * 1962-10-11 1966-03-08 Vitamix Pharmaceuticals Inc Gelatin composition
FR2042381A1 (en) * 1969-04-28 1971-02-12 Knox Gelatine Inc
DE3138094A1 (en) * 1980-09-25 1982-05-06 Yamanouchi Pharmaceutical Co., Ltd., Tokyo AGENT FOR IMPROVING BLOOD CIRCULATION

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3239420A (en) * 1962-10-11 1966-03-08 Vitamix Pharmaceuticals Inc Gelatin composition
FR2042381A1 (en) * 1969-04-28 1971-02-12 Knox Gelatine Inc
DE3138094A1 (en) * 1980-09-25 1982-05-06 Yamanouchi Pharmaceutical Co., Ltd., Tokyo AGENT FOR IMPROVING BLOOD CIRCULATION

Similar Documents

Publication Publication Date Title
Ebashi Third component participating in the super precipitation of ‘natural actomyosin’
US2414299A (en) Production of protein hydrolysate flavoring material
YAMASHINA et al. The properties of a carbohydrate-amino acid complex from ovalbumin
NO147575B (en) FLEXIBLE ELEMENT FOR USE IN OPTICAL TRANSFER
US2180637A (en) Amino acids product and method of manufacture
ES2003197A6 (en) Process for the depolymerization of heparin for obtaining heparin with a low molecular weight and having an antithrombotic activity.
US4064008A (en) Gelatin extraction
GB886553A (en) Substitutes for blood plasma and process for their manufacture
US3057782A (en) Cross-linked gelatin plasma substitute and production thereof
KR20030074577A (en) Process for preparing sterilized pure water-soluble collagen peptide
Zwaig et al. The amino acid sequence around the reactive serine residue in alkaline phosphatase of Serratia marcescens
US3623950A (en) Enzymatic dehairing process
Kato et al. Deamidation of ovalbumin during S-ovalbumin conversion
US2816099A (en) Process of making urea derivatives of proteins
ES8600652A1 (en) Process for tanning hides.
ES8307019A1 (en) Method of making water-soluble or self-dispersing resinous tanning agents and their use.
Van Slyke THE FATE OF PROTEIN DIGESTION PRODUCTS IN THE BODY. II. DETERMINATION OF AMINO NITROGEN IN THE TISSUES.
Prayitno et al. Sheep wool-derived hydrolyzed keratin from tannery waste of the tanning industry using perhydrol
ATE32718T1 (en) PROCESS FOR THE PRODUCTION OF (S)GLYCERALDEHYDACETONIDE.
US3455894A (en) Process of preparing high potency iodinated protein which comprises reacting said protein with ba(oh)2 at a temperature of at least 110 c.
GB1175622A (en) Improvements in or relating to Collagen Films and Filaments and the Manufacture thereof
US1253334A (en) Ferments and process of making the same.
US2309188A (en) Treatment of hides
Lillie On the effects of various solutions on ciliary and muscular movement in the larvae of Arenicola and Polygordius. II
SU442800A1 (en) The method of obtaining the drug for parenteral protein nutrition